中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Issue 12
Dec.  2016

Association between portal vein pressure drop gradient after transjugular intrahepatic portosystemic shunt and clinical prognosis

DOI: 10.3969/j.issn.1001-5256.2016.12.019
  • Published Date: 2016-12-20
  • Objective To investigate the association between portal vein pressure drop gradient in patients with cirrhotic portal hypertension treated by transjugular intrahepatic portosystemic shunt( TIPS) and clinical prognosis,as well as the ideal range of portal vein pressure drop. Methods A total of 58 patients who underwent TIPS in Xinqiao Hospital of Third Military Medical University from November 2013 to December 2015 were enrolled. All the patients underwent TIPS and embolization of the gastric coronary vein and the short gastric veins,and the change intervals of portal vein pressure gradient were monitored. The follow- up time ranged from 3 days to 2 years,and the association of portal vein pressure drop gradient with postoperative liver function,splenic function,rebleeding rate,hepatic encephalopathy,and portal hypertensive gastrointestinal diseases was analyzed. The paired t- test was used for comparison of parameters before and after treatment. Results The patients had a significant reduction in liver function on day 3 after surgery. At 2 month after surgery,the levels of TBil was rised and had significant changes[( 49. 81 ± 27. 82) μmol/L vs( 31. 64 ± 17. 67) μmol/L,t = 5. 372,P < 0. 001]. At 6 months after surgery,red blood cell count and platelet count had no significant changes,but,white blood cell count was reduced[( 3. 79 ± 1. 37) ×10~9/L vs( 4. 57 ±2. 24) ×10~9/L,t = 2. 835,P = 0. 006]. There was a 23% reduction in portal vein pressure after surgery( from 30. 62 ± 3. 56 mm Hg before surgery to 21. 21 ± 2. 90 mm Hg after surgery,t = 23. 318,P < 0. 001). All the patients had varying degrees of relief of gastrointestinal symptoms associated with portal vein hypertension,such as abdominal distension,poor appetite,and diarrhea. Of all patients,none experienced in- stent restenosis or occlusion and 13 experienced hepatic encephalopathy after surgery,which tended to occur at the time when postoperative portal vein pressure was reduced to 14. 7- 25. 7 mm Hg,i. e.,a 36%- 40% reduction in portal vein pressure. The results of splenic venography performed immediately after surgery showed that varicose veins almost disappeared and that there were no collateral varices. Gastroscopy was performed again within 1 month after surgery and 5 patients had no significant changes in esophageal varices. The other patients were followed up for 2 years,and the severity of esophageal and gastric varices gradually changed from severe varices with red color sign to moderate and mild varices and even disappeared. The proportion of patients with mild and disappeared varices increased from 22% on day 3after surgery to 52% in the second year after surgery. No patients experienced rebleeding within 1 month after surgery. Six patients each experienced rebleeding at 2,6,10,14,16,and 24 months after surgery,and in one patient,duodenal bulbar ulcer and bleeding was not excluded; the other 5 patients experienced gastric variceal bleeding again,with a median portal vein pressure of 36. 46 mm Hg before surgery and 24. 8 mm Hg after surgery,with a 32% reduction in portal vein pressure. Conclusion TIPS has a good clinical effect in hemostasis and prevention of rebleeding in patients with cirrhotic portal hypertension and can control the portal vein pressure below 21. 21 ± 2. 90 mm Hg,and the degree of reduction in portal vein pressure is below 36%- 40%. It can reduce the incidence of postoperative rebleeding and avoid the development of hepatic encephalopathy. TIPS can cause liver impairment within a short period of time after surgery,and liver function can return to normal within 1- 6 months after surgery,but splenic function does not recover significantly.

     

  • [1]LEE JY,KIM TY,JEONG WK,et al.Clinically severe portal hypertension:role of multi-detector row CT features in diagnosis[J].Dig Dis Sci,2014,59(9):2333-2343.
    [2]ZENG DB,DAI CZ,LU SC,et al.Abnormal splenic artery diameter/hepatic artery diameter ratio in cirrhosis-induced portal hypertension[J].World J Gastroenterol,2013,19(8):1292-1298.
    [3]ZHENG LL,HAN GH,FAN DM.Role of transjugular intrahepatic portosytemic shunt in prevention and treatment of variceal bleeding liver cirrhosis[J].J Clin Hepatol,2014,30(7):687-690.(in Chinese)郑鸾鸾,韩国宝,樊代明.经颈静脉肝内门体分流术在肝硬化静脉曲张出血防治中的地位[J].临床肝胆病杂志,2014,30(7):687-690.
    [4]BERCU ZL,SHETH SB,NOOR A,et al.Percutaneous mesocaval shunt creation in a patient with chronic portal and superior mesenteric vein thrombosis[J].Cardiovasc Intervent Radiol,2015,38(5):1316-1319.
    [5]PAU V,SUSOCKI MD,MATTHEW P,et al.Transjugular intrahepatic portosystemic shunt complications:prevention and management[J].Semin Intervent Rad,2015,32:123-132.
    [6]PATAL NH,SASADEUSZ KJ,SESHADRI R,et al.Increase in hcpatic arterialblood flow after ransjugular intrahepatic portosystemicshunt creation and its potential predictive value of postproccdural encephalopathy and mortality[J].J Vase Intcrv Radiol,2001,12(11):1279-1284.
    [7]CHENG SB.A retrospective study of 42 death cases with decompensated hepatocirrhosis[J].Anhui Med Pharm J,2006,10(4):285-286.(in Chinese)程四八.42例肝硬化失代偿期死亡病例回顾性分析[J].安徽医药,2006,10(4):285-286.
    [8]YANG L,YUAN LJ,DONG R,et al.Two surgical procedures for esophagogastric variceal bleeding in patients with portal hypertension[J].World J Gastroenterol,2013,19(48):9418-9424.
    [9]YANG H.Clinical effect of endoscopic sclerosing agent treatment for esophageal variceal bleeding[J].Shandong Med J,2010,50(36):90-91.(in Chinese)杨惠.内镜下硬化剂治疗食管静脉曲张破裂出血临床研究[J].山东医药,2010,50(36):90-91.
    [10]LU HY,HUANG FZ,NIE WP,et al.Treatment selection for hepatocirrhosis portal hypertension patients with recurrent hemorrhage after endoscopic variceal ligation[J/CD].Chin J Hepat Surg:Electronic Edition,2012,1(2):79-84.(in Chinese)卢焕元,黄飞舟,聂晚频,等.肝硬化门静脉高压症患者食管静脉曲张套扎术后复发再出血治疗方法的选择[J/CD].中华肝脏外科手术学电子杂志,2012,1(2):79-84.
    [11]GARCIA TG,BOSCH J.Varices and variceal hemorrhage in cirrhosis:a new view of an old problem[J].Clin Gastroenterol Hepatol,2015,13(12):2109-2117.
    [12]KRUEL CR,GUIMARAES M,Ch EDID AD,et al.Bilhemia following transjugular intrahepatic portosystemic shunt placement(Tips):liver transplantation as a rescue procedure-case report[J].Arq Bras Cir Dig,2013,26(3):238-240.
    [13]BAYRAKTAR Y,BALKANCI F,OZENC A,et al.The“pseudocholangiocarcinoma sign”in patients with cavernous transformation of the portal vein and its effect on the serum alkaline phosphatase and bilirubin levels[J].Am J Gastroenterol,1995,90(11):2015-2019.
    [14]SUDHEER SP,SALONI ND,VAIBHAV PS,et al.Imaging and radiological interventions in extra-hepatic portal vein obstruction[J].World J Radiol,2016,8(6):556-570.
    [15]QA XH,HAN G,HE C,et al.Transjugular intrahepatic portosystemic shunt may be superior to conservative therapy for variceal rebleeding in cirrhosis patients with non-tumoral portal vein thrombosis:ahypothesis[J].Med Sci Monit,2012,18(8):37-41.
    [16]ZHANG HF.Medical treatment of upper gastrointestinal bleeding in patients with cirrhosis[J].Chin J Pract Intern Med,2010,30(11):974-976.(in Chinese)张鸿飞.肝硬化合并上消化道出血临床治疗[J].中国实用内科杂志,2010,30(11):974-976.
    [17]ORLOFF MJ.Fifty-three years’experience with randomized clinical trials of emergency portacaval shunt for bleeding esophageal varices in cirrhosis:1958-2011[J].JAMA Surg,2014,149(2):155-169.
    [18]ZIPPRICH A,GARCIA TG,ROGOWSKI S,et al.Prognostic indicators of survival in patients with compensated and decompensated cirrhosis[J].Liver Int,2012,32(9):1407-1414.
    [19]XUE H,ZHANG M,PANG JX,et al.Transjugular intrahepatic portosystemic shunt vs endoscopic therapy in preventing variceal rebleeding[J].World J Gastroenterol,2012,18(48):7341-7347.
    [20]HE FL,WANG L,YUE ZD,et al.Parallel transjugular intrahepatic portosystemic shunt for controlling portal hypertension complications in cirrhotic patients[J].World J Gastroenterol,2014,20(33):11835-11839.
  • Relative Articles

    [1]Mengying LIU, Weizhi LI, Peijie LI, Fuquan MA, Yuling CHEN, Huanhuan SUN, Tiantian GAO, Hui XUE. Comparison of endoscopic therapy and TIPS in prophylaxis and treatment of variceal bleeding in decompensated portal hypertension[J]. Journal of Clinical Hepatology, 2023, 39(7): 1529-1534. doi: 10.3969/j.issn.1001-5256.2023.07.003
    [2]Bowen CHEN, Jiamin CHENG, Linzhi ZHANG, Jin LEI, Xiaoqiang GAO, Yinying LU. Effect of the treatment modality for hepatocellular carcinoma on portal venous pressure[J]. Journal of Clinical Hepatology, 2022, 38(7): 1658-1661. doi: 10.3969/j.issn.1001-5256.2022.07.038
    [3]Zhen LI, Chunqing ZHANG. Esophageal and gastric variceal bleeding in liver cirrhosis: Embolization or shunt[J]. Journal of Clinical Hepatology, 2021, 37(12): 2764-2766. doi: 10.3969/j.issn.1001-5256.2021.12.004
    [4]Huang Shan, Zhou Hao, Chen XueLing, Yao Xin, Tang ShanHong, Yang GuoDong, Qin JianPing. Effect of transjugular intrahepatic portosystemic shunt on the liver and the heart[J]. Journal of Clinical Hepatology, 2020, 36(4): 904-907. doi: 10.3969/j.issn.1001-5256.2020.04.043
    [5]Guo Shuai, Han GuoHong. Safety and efficacy of transjugular intrahepatic portosystemic shunt in treatment of acute decompensated cirrhotic events in patients with acute-on-chronic liver failure[J]. Journal of Clinical Hepatology, 2020, 36(4): 818-822. doi: 10.3969/j.issn.1001-5256.2020.04.022
    [6]Yao Xin, Zhou Hao, Tang ShanHong, Huang Shan, Chen XueLing, Qin JianPing. Effect of intraoperative Viatorr stent implantation for shunting of blood flow in the left or right branch of the portal vein and its effect on clinical outcome in patients with cirrhotic portal hypertension undergoing transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2020, 36(9): 1970-1974. doi: 10.3969/j.issn.1001-5256.2020.09.012
    [7]ZHANG Han, XIAO JiangQiang, ZHANG Ming, ZHANG Feng, ZHU GeYuZheng. Balloon-occluded retrograde transvenous obliteration for treating recurrent bleeding after transjugular intrahepatic portosystemic shunt: A report of 2 cases[J]. Journal of Clinical Hepatology, 2020, 36(12): 2798-2800. doi: 10.3969/j.issn.1001-5256.2020.12.031
    [8]The Chinese College of Interventionalists. CCI clinical practice guidelines: Management of TIPS for portal hypertension (2019 edition)[J]. Journal of Clinical Hepatology, 2019, 35(12): 2694-2699. doi: 10.3969/j.issn.1001-5256.2019.12.010
    [9]Li Jing, Jiang Yong, Zhang Xu. Efficacy of transjugular intrahepatic portosystemic shunt versus endoscopic cyanoacrylate injection in treatment of gastric variceal bleeding: A meta-analysis[J]. Journal of Clinical Hepatology, 2019, 35(2): 349-353. doi: 10.3969/j.issn.1001-5256.2019.02.021
    [10]Ding ZhiFeng, Yin ShiWu. Application of Viatorr covered stent in transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2018, 34(5): 1107-1110. doi: 10.3969/j.issn.1001-5256.2018.05.039
    [11]Chen Min, Zhang Feng, Zhang Ming, Li ZhenLei, He QiBin, Mou ChengCheng, Zhong WenQi, Zhu GeYuZheng. Clinical effect of transjugular intrahepatic portosystemic shunt combined with tissue adhesive embolization in treatment of gastroesophageal variceal rebleeding in cirrhotic patients[J]. Journal of Clinical Hepatology, 2018, 34(6): 1209-1214. doi: 10.3969/j.issn.1001-5256.2018.06.016
    [12]Interventional Group, Chinese Society of Radiology, Chinese Medical Association. Expert consensus on transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2017, 33(7): 1218-1228. doi: 10.3969/j.issn.1001-5256.2017.07.004
    [13]Tuo Lin, Tang ShanHong, Zeng WeiZheng, Wu XiaoLing. Treatment and prevention strategies to complications of transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2016, 32(2): 354-357. doi: 10.3969/j.issn.1001-5256.2016.02.034
    [14]Xue Hui, Li PeiJie, Li WeiZhi, Su JingWen, Huang Jin. Prevention and treatment of complications after transjugular intrahepatic portosystemic shunt[J]. Journal of Clinical Hepatology, 2016, 32(2): 238-241. doi: 10.3969/j.issn.1001-5256.2016.02.007
    [15]Xiao JiangQiang, ZhuGe YuZheng. Advances in transjugular intrahepatic portosystemic shunt and its application in treatment of cirrhotic portal hypertension[J]. Journal of Clinical Hepatology, 2016, 32(2): 234-237. doi: 10.3969/j.issn.1001-5256.2016.02.006
    [16]Niu Meng, Sun Jun, Xu Ke, Zhong HongShan. Retrospects and prospects of transjugular intrahepatic portosystemic shunt in China[J]. Journal of Clinical Hepatology, 2016, 32(2): 230-233. doi: 10.3969/j.issn.1001-5256.2016.02.005
    [17]Zheng LuanLuan, Han GuoHong, Fan DaiMing. Role of transjugular intrahepatic portosystemic shunt in prevention and treatment of variceal bleeding in liver cirrhosis[J]. Journal of Clinical Hepatology, 2014, 30(7): 687-690. doi: 10.3969/j.issn.1001-5256.2014.07.031
    [18]Wu JiYuan, Zhang DongQin, Zhang HaiYue, Wang LuWen, Gong ZuoJiong. Efficacy and safety of transjugular intrahepatic portosystemic shunt versus endoscopic therapy for prevention of variceal rebleeding in patients with cirrhosis: a meta-analysis[J]. Journal of Clinical Hepatology, 2014, 30(12): 1272-1278. doi: 10.3969/j.issn.1001-5256.2014.12.010
    [19]Shao CuiPing, Xu XiaoYuan. Progress in the prevention and treatment of bleeding gastroesophageal varices in patients with cirrhosis[J]. Journal of Clinical Hepatology, 2012, 28(9): 647-650.
    [20]Wang JiYao. Importance of detecting portal hypertension in liver cirrhosis patients: theory, research tools, and clinical applications[J]. Journal of Clinical Hepatology, 2012, 28(9): 642-643.
  • Cited by

    Periodical cited type(7)

    1. 单航声,蒋明明,徐浩,张庆桥,魏宁,许伟,崔艳峰,刘洪涛,顾玉明,祖茂衡,王文亮,高志康. 改良经颈静脉肝内门体分流术治疗布-加综合征所致顽固性腹水效果分析. 介入放射学杂志. 2021(03): 235-238 .
    2. 耿旭,沙俊诚,徐浩,张庆桥,魏宁,许伟,顾玉明,徐凯,祖茂衡. 广泛肝静脉闭塞性布加综合征TIPS术后肝脏体积及肝功能变化. 中华肝胆外科杂志. 2021(06): 434-437 .
    3. 邹松龙,胥莹. 经颈静脉肝内门体分流术治疗肝硬化门静脉高压症的预后评估. 临床肝胆病杂志. 2019(01): 201-204 . 本站查看
    4. 秦军,蔡婵娟,刘雨晴. TIPS联合冠状静脉栓塞术治疗门脉高压性上消化道出血的疗效及安全性分析. 现代消化及介入诊疗. 2019(11): 1288-1291 .
    5. 彭素妤,林健玲. 超声检查在肝硬化患者经颈静脉肝内门静脉内支架分流术后的应用分析. 中外医学研究. 2018(26): 75-77 .
    6. 张艳飞,陈平. 经颈静脉肝内门体静脉分流术的预后研究进展. 中国微创外科杂志. 2018(05): 457-461 .
    7. 赵玉龙,刘顺顺,姚德炯,梁伟军,黄辉,王忠伟. 经颈静脉肝内门体分流术治疗肝硬化门静脉高压症的临床研究. 中国医药导报. 2018(28): 81-84 .

    Other cited types(7)

  • Created with Highcharts 5.0.7Amount of accessChart context menuAbstract Views, HTML Views, PDF Downloads StatisticsAbstract ViewsHTML ViewsPDF Downloads2024-052024-062024-072024-082024-092024-102024-112024-122025-012025-022025-032025-0405101520
    Created with Highcharts 5.0.7Chart context menuAccess Class DistributionFULLTEXT: 4.6 %FULLTEXT: 4.6 %META: 91.0 %META: 91.0 %PDF: 4.4 %PDF: 4.4 %FULLTEXTMETAPDF
    Created with Highcharts 5.0.7Chart context menuAccess Area Distribution其他: 8.6 %其他: 8.6 %其他: 0.2 %其他: 0.2 %India: 0.2 %India: 0.2 %Macau: 0.6 %Macau: 0.6 %上海: 2.7 %上海: 2.7 %中卫: 0.2 %中卫: 0.2 %佳木斯: 0.2 %佳木斯: 0.2 %兰州: 1.9 %兰州: 1.9 %北京: 12.5 %北京: 12.5 %华盛顿州: 0.2 %华盛顿州: 0.2 %南宁: 0.2 %南宁: 0.2 %台州: 0.2 %台州: 0.2 %吉林: 0.8 %吉林: 0.8 %哥伦布: 0.2 %哥伦布: 0.2 %大连: 0.2 %大连: 0.2 %张家口: 3.5 %张家口: 3.5 %德阳: 0.2 %德阳: 0.2 %成都: 0.2 %成都: 0.2 %昆明: 0.4 %昆明: 0.4 %朝阳: 0.4 %朝阳: 0.4 %杭州: 0.6 %杭州: 0.6 %武汉: 0.2 %武汉: 0.2 %洛阳: 0.2 %洛阳: 0.2 %济宁: 0.2 %济宁: 0.2 %海口: 0.2 %海口: 0.2 %淄博: 0.2 %淄博: 0.2 %湖州: 0.2 %湖州: 0.2 %澳门: 0.4 %澳门: 0.4 %石家庄: 0.4 %石家庄: 0.4 %福州: 0.2 %福州: 0.2 %芒廷维尤: 28.0 %芒廷维尤: 28.0 %芝加哥: 0.6 %芝加哥: 0.6 %苏州: 0.2 %苏州: 0.2 %莫斯科: 1.7 %莫斯科: 1.7 %西宁: 29.9 %西宁: 29.9 %西安: 0.4 %西安: 0.4 %赤峰: 0.2 %赤峰: 0.2 %运城: 0.4 %运城: 0.4 %重庆: 0.2 %重庆: 0.2 %银川: 0.4 %银川: 0.4 %长春: 0.2 %长春: 0.2 %长沙: 0.4 %长沙: 0.4 %长治: 0.2 %长治: 0.2 %阳泉: 0.2 %阳泉: 0.2 %青岛: 0.2 %青岛: 0.2 %其他其他IndiaMacau上海中卫佳木斯兰州北京华盛顿州南宁台州吉林哥伦布大连张家口德阳成都昆明朝阳杭州武汉洛阳济宁海口淄博湖州澳门石家庄福州芒廷维尤芝加哥苏州莫斯科西宁西安赤峰运城重庆银川长春长沙长治阳泉青岛

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Article Metrics

    Article views (2108) PDF downloads(541) Cited by(14)
    Proportional views
    Related

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return